Innoviva

INVA

時価総額 $15億

Investors need to pay close attention to INVA stock based on the movements in the options market lately.

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors?

DINO, INVA, PARR, GNW and PBF stand out as low price-to-sales stocks with promising upside potential. Discover how attractive valuations can uncover hidden value.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.

In August, we welcomed 25 new analysts to Seeking Alpha. This article showcases their stock picks and investment strategies. Analysts provided ratings from Strong Sell to Strong Buy, with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bullish views on CTO Realty, Allogene Therapeutics, NanoXplore, Modine, and 3i Group.

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: Citi's 2026 Biopharma Back to School Conference F.

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company's infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics prod.

Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.

Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.